Lab automation or robotic scientists: Dr McClymont and Professor Freemont share their views in Nature Biotechnology
- Posted on 12 April
Dr David McClymont, head of automation at the London DNA Foundry, and Professor Paul Freemont, Co-director of the London DNA Foundry and the EPSRC Centre for Synthetic Biology and Innovation at Imperial College London, have co-authored an article appearing in April in Nature Biotechnology. The article, entitled ‘With all due respect to Maholo, Lab Automation isn’t anthropomorphic’, will discuss the virtues of building on existing automation technologies in lab research over humanoid robotic lab infrastructure. That is to say, automating the process rather than the scientist.
The view that anthropomorphic robots are the future of laboratory research is based on the assumption that using human-friendly hand tools is the optimal way to carry out experiments. However, this is not necessarily the case, as Dr McClymont and Professor Freemont discuss, citing both the challenges and benefits of non-humanoid robot automated processes.
Laboratory automation has matured over the past 30 years to solve specific problems, carrying out experiments in efficient ways that do not mimic human movements. What we need now is to alter our perception of automation by providing accessible, open source and inexpensive hardware solutions to routine ‘wetlab’ protocols and assay measurements.
The full article is available at Nature Biotechnology (http://www.nature.com/nbt/journal/v35/n4/full/nbt.3795.html)
Share this article:
People also read
East African Collaborations in Practical Synthetic Biology Workshop
From the 15th-17th March 2017 SynbiCITE will attend a workshop to establish UK-East African collaborations in practical synthetic biology, taking plac...
SynbiCITE is a proud sponsor of the ‘Best Emerging UK Synthetic Biology Company’ at the OBN Awards 2017
SynbiCITE is pleased to announce once again they will be sponsoring the ‘Best Emerging UK Synthetic Biology Company’ at the 9th Annual OBN Awards, 2017. This award recognises the emerging industrial or synthetic biology company that has the most promise.
Bio-start Selects First Cohort: 15 companies join Bio-start’s inaugural synthetic biology accelerator
Bio-start is pleased to announce the 15 companies that will be joining the UK’s first synthetic biology accelerator programme. Applicants from across ...